Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Justine Leonie Kuiper
Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Justine Leonie Kuiper
Thesis, Faculty of Medicine, VU University medical center, VU University, The Netherlands

Author: Justine Leonie Kuiper
Cover illustration: Nicole Nijhuis - Gildeprint
Lay-out and printing: Gildeprint, Enschede

Copyright © J.L. Kuiper, the Netherlands, 2016

All rights reserved. No parts of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without written permission from the author or from the Publisher holding the copyright of the published articles.

Publication of this thesis was financially supported by:
Boehringer Ingelheim B.V., Vrije Universiteit Amsterdam, Chipsoft, AstraZeneca

The research in this thesis was performed at the Department of Pulmonary Diseases of the VU University medical center, Amsterdam, the Netherlands.
Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

ACADEMISCH PROEFSCHRIFT

ter verkrijging van de graad Doctor aan
de Vrije Universiteit Amsterdam,
op gezag van de rector magnificus
prof.dr. V. Subramaniam,
in het openbaar te verdedigen
ten overstaan van de promotiecommissie
van de Faculteit der Geneeskunde
op donderdag 8 december 2016 om 9.45 uur
in de aula van de universiteit,

de Boelelaan 1105

door

Justine Leonie Kuiper

geboren te Rheden
promotor: prof.dr. E.F. Smit
copromotor: dr. D.A.M. Heideman
Voor mijn ouders
## CONTENT

### Introduction

**Ch. 1:** Introduction and outline of this thesis  
9

### Diagnostics & response prediction

**Ch. 2:** Non-classic *EGFR*-mutations in a cohort of Dutch *EGFR*-mutated NSCLC-patients and outcomes following EGFR-TKI treatment  
Accepted for publication in British Journal of Cancer  
29

**Ch. 3:** Incidence of T790M mutation in (sequential) rebiopsies in *EGFR*-mutated NSCLC-patients  
51

**Ch. 4:** Ch. 4a: Detecting resistance in *EGFR*-mutated NSCLC after clonal selection through targeted therapy  
*Personalized Medicine* 2015 Apr;12(2): 63-6  
69

**Ch. 4b:** Transformation to a squamous cell carcinoma phenotype of an *EGFR*-mutated NSCLC-patient after treatment with an EGFR-tyrosine kinase inhibitor  
*Journal of Clinical Pathology* 2015 Apr;68(4):320-1  
75

**Ch. 5:** VeriStrat® has prognostic value in advanced stage NSCLC-patients treated with erlotinib and sorafenib  
81

### Treatment

**Ch. 6:** Challenges in the management of *EGFR*-mutated non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors  
*Oncology* 2014;87(2):83-94  
97

**Ch. 7:** Treatment and survival of patients with *EGFR*-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis  
*Lung Cancer* 2015 Sep;89(3):255-61  
115

**Ch. 8:** Ch. 8a: High-dose, pulsatile erlotinib in two NSCLC-patients with leptomeningeal metastases – one with a remarkable thoracic response as well  
*Lung Cancer* 2013 Apr;80(1):102-5  
131

**Ch. 8b:** High-dose, weekly erlotinib is not an effective treatment in *EGFR*-mutated non-small cell lung cancer patients with acquired extracranial progressive disease on standard dose erlotinib  
Adapted from: *European Journal of Cancer* 2014 May;50(7):1399-401  
139
Ch. 9: Outcome on afatinib in NSCLC-patients who progressed on prior treatment with erlotinib or gefitinib

*In progress*

**Discussion**

Ch. 10: Ch. 10a: Summary and future perspectives 165
Ch. 10b: Dutch summary (Nederlandse samenvatting) 177

Curriculum Vitae 187
Dankwoord 189
List of publications 195